International Journal of Hematology最新文献_第2页

Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients. B-ALL患者对免疫治疗药物（包括blinatumomab和inotuzumab ozogamicin）的反应差异

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-04-15 DOI: 10.1007/s12185-025-03983-5

Zhi-Yin Liu, Ze-Ying Yan, Jian-Feng Li, Yong-Mei Zhu, Guang Yang, Hai-Min Sun, Ran An, Jie Tian, Ying Wang, Xiao-Qian Xu, Li Chen, Wei-Ying Bao, Su-Jiang Zhang

{"title":"Differences in response to immunotherapy drugs including blinatumomab and inotuzumab ozogamicin in B-ALL patients.","authors":"Zhi-Yin Liu, Ze-Ying Yan, Jian-Feng Li, Yong-Mei Zhu, Guang Yang, Hai-Min Sun, Ran An, Jie Tian, Ying Wang, Xiao-Qian Xu, Li Chen, Wei-Ying Bao, Su-Jiang Zhang","doi":"10.1007/s12185-025-03983-5","DOIUrl":"10.1007/s12185-025-03983-5","url":null,"abstract":"The treatment of B-cell precursor acute lymphoblastic leukemia (B-ALL) has undoubtedly transitioned into the immunotherapy era. We conducted a retrospective study on B-ALL immunotherapy, especially regimens including blinatumomab (Blina) and inotuzumab ozogamicin (InO), at our center. A total of 21 B-ALL patients were involved in this study, including 18 with newly diagnosed (ND) B-ALL and 3 with relapsed B-ALL. RNA sequencing identified a total of five new fusions (ADD1::JAK2, PVT1::IGLL5, PAX5::KANK2, ETV6::BCL2L14, and CDKN2A::TGFBR3) in five different patients. All ND patients can be divided into four groups according to treatment response. Group 1, which included patients with PAX5::KANK2 and CREBBP::ZNF384, responded best to Blina. Group 2, which included one patient with CDKN2A::TGFBR3 fusion and one who was BCR::ABL positive, showed an inferior response to Blina compared with Group 1. Group 3 initially showed no response but subsequently responded very favorably to InO and showed further improvement with Blina. Group 4, which included patients with PVT1::IGLL5 fusion, had the poorest prognosis. In conclusion, Blina and InO showed specific treatment advantages for different patient groups in our cohort that may be attributed to intrinsic genetic characteristics, such as new fusion genes.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"295-300"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144015347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JSH practical guidelines for hematological malignancies, 2023: II. lymphoma 9-adult T-cell leukemia-lymphoma (ATL). 恶性血液病实用指南，2023:II。成人t细胞白血病淋巴瘤（ATL）。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-06-04 DOI: 10.1007/s12185-025-04011-2

Kisato Nosaka, Takuya Fukushima

引用次数: 0

JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 8. Extranodal NK/T-cell lymphoma, nasal type (ENKL). 恶性血液病实用指南，2023:II。淋巴瘤8。结外NK/ t细胞淋巴瘤鼻型（ENKL）。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-06-12 DOI: 10.1007/s12185-025-04019-8

Dai Maruyama, Makoto Yoshimitsu

引用次数: 0

Distinct impact of letermovir discontinuation on tacrolimus pharmacokinetics based on concomitant azole antifungal agent. 停药对他克莫司药代动力学的显著影响。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-06-16 DOI: 10.1007/s12185-025-04017-w

Sotaro Goto, Daichi Sadato, Takashi Toya, Akihiro Shimizu, Koki Narita, Hiroaki Shimizu, Yuho Najima, Yasuhiko Yamamura, Noriko Doki

{"title":"Distinct impact of letermovir discontinuation on tacrolimus pharmacokinetics based on concomitant azole antifungal agent.","authors":"Sotaro Goto, Daichi Sadato, Takashi Toya, Akihiro Shimizu, Koki Narita, Hiroaki Shimizu, Yuho Najima, Yasuhiko Yamamura, Noriko Doki","doi":"10.1007/s12185-025-04017-w","DOIUrl":"10.1007/s12185-025-04017-w","url":null,"abstract":"Letermovir can effectively prevent clinically significant cytomegalovirus infections following allogeneic hematopoietic stem cell transplantation (HCT). Although some antifungal agents influence the pharmacokinetics of tacrolimus after the discontinuation of letermovir, the effect of posaconazole (PSCZ) has not been previously described. This study retrospectively evaluated the association between azole type and tacrolimus pharmacokinetics before and after discontinuation of letermovir prophylaxis. The analysis included 89 patients who underwent HCT at our hospital. In the PSCZ group, the tacrolimus concentration-to-dose (C/D) ratio after letermovir discontinuation was significantly higher than that observed before discontinuation (median 7.91 vs 6.50, P = 0.004). The fold-change in the C/D ratio (post-/pre-discontinuation) was significantly higher in the PSCZ group compared with the fluconazole group (median 1.23 vs 0.83, P = 0.003). These findings suggest that tacrolimus pharmacokinetics after letermovir discontinuation in HCT recipients vary depending on which concomitant azole antifungal agent is used. Furthermore, the tacrolimus C/D ratio could increase following letermovir discontinuation in patients receiving PSCZ. Careful monitoring of tacrolimus concentrations at letermovir discontinuation is crucial to avoid an unexpected reversal of tacrolimus concentrations and prevent adverse events.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":"199-205"},"PeriodicalIF":1.8,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144302026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

JSH practical guidelines for hematological malignancies, 2023: II. Lymphoma 7. Peripheral T-cell lymphoma (PTCL). 恶性血液病实用指南，2023:II。淋巴瘤7。周围t细胞淋巴瘤（PTCL）。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-08-01 Epub Date: 2025-06-12 DOI: 10.1007/s12185-025-04018-9

Dai Maruyama, Makoto Yoshimitsu

引用次数: 0

Treatment of post-transplant lymphoproliferative disorders in kidney transplant recipients: a single-center retrospective analysis. 肾移植受者移植后淋巴增生性疾病的治疗：单中心回顾性分析。

IF 1.8 4区医学

International Journal of Hematology Pub Date : 2025-07-28 DOI: 10.1007/s12185-025-04039-4

Futoshi Yoshino, Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Atsushi Wake, Go Yamamoto

{"title":"Treatment of post-transplant lymphoproliferative disorders in kidney transplant recipients: a single-center retrospective analysis.","authors":"Futoshi Yoshino, Daisuke Kaji, Otoya Watanabe, Kyosuke Yamaguchi, Kosei Kageyama, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Hisashi Yamamoto, Yuki Asano-Mori, Naoyuki Uchida, Atsushi Wake, Go Yamamoto","doi":"10.1007/s12185-025-04039-4","DOIUrl":"https://doi.org/10.1007/s12185-025-04039-4","url":null,"abstract":"Post-transplant lymphoproliferative disorder (PTLD) is a significant complication of immunosuppression after kidney transplantation and has no established standard therapy. Achieving favorable treatment outcomes and preserving renal function in patients with PTLD remains challenging, particularly when the central nervous system (CNS) is involved. Here we describe our experience with 8 patients who developed PTLD after kidney transplantation at our institution. Diffuse large B-cell lymphoma was the most common histological subtype, observed in 5 patients (62.5%). Epstein-Barr Virus infections were observed in 7 patients (87.5%), CNS involvement in 5 patients (62.5%) and gastrointestinal tract involvement in 3 patients (37.5%). With a median follow-up of 55.3 months, the 4-year overall survival rate was 72.9%. Seven patients (87.5%) achieved complete remission (CR), and 5 maintained CR as of the last follow-up visit. In the CNS involvement group, patients treated with aggressive chemotherapy died of sepsis, and those treated with a combination of rituximab, whole-brain radiation therapy, and reduction of immunosuppression achieved long-term progression-free survival without reinstitution of dialysis or neurological toxicity. The clinical courses of these 8 kidney transplant recipients who developed PTLD, most of whom had CNS involvement, suggest that long-term remission may be achievable without systemic chemotherapy.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144730309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysis. 造血干细胞移植后体液免疫：用b细胞受体库分析评价。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-07-25 DOI: 10.1007/s12185-025-04042-9

Sakuya Matsumoto, Yohei Funakoshi, Kimikazu Yakushijin, Takaji Matsutani, Yuri Okazoe-Hirakawa, Goh Ohji, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Naomi Kiyota, Hironobu Minami

{"title":"Humoral immunity after hematopoietic stem cell transplantation: evaluation by B-cell receptor repertoire analysis.","authors":"Sakuya Matsumoto, Yohei Funakoshi, Kimikazu Yakushijin, Takaji Matsutani, Yuri Okazoe-Hirakawa, Goh Ohji, Taiji Koyama, Yoshiaki Nagatani, Keiji Kurata, Shiro Kimbara, Naomi Kiyota, Hironobu Minami","doi":"10.1007/s12185-025-04042-9","DOIUrl":"https://doi.org/10.1007/s12185-025-04042-9","url":null,"abstract":"Immunity acquired before hematopoietic stem cell transplantation (HSCT) may decrease or disappear following HSCT, and it is unclear whether the first vaccination after HSCT in patients with an antigen exposure history before HSCT elicits a primary or secondary immune response. The Quantification of Antigen-Specific Antibody Sequence (QASAS) method enables real-time assessment of responses to SARS-CoV-2 antigen exposure through B-cell receptor (BCR) repertoire analysis. Using this method, we evaluated the disappearance of immunological memory after HSCT. First, in individuals without hematologic disorders, primary SARS-CoV-2 antigen exposure elicited no immune response at 7 days post-exposure but demonstrated activation between 14 to 21 days. In contrast, repeated exposure elicited early responses (secondary immune responses) at 7 days post-exposure. We then enrolled HSCT patients with pre-HSCT SARS-CoV-2 antigen exposure history and collected samples before and after vaccination. Despite prior exposure history, patients receiving their first vaccination after HSCT showed no response around 7 days post-exposure but responded at 14 days. In conclusion, even with pre-HSCT antigen exposure, the first vaccination after HSCT induced a primary immune response. This demonstrates that first vaccination after HSCT should be considered to induce a primary immune response, regardless of previous infection or vaccination history.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression profiling of Epstein-Barr virus-derived microRNA in systemic chronic active EBV disease. eb病毒衍生的microRNA在系统性慢性活动性EBV疾病中的表达谱

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-07-25 DOI: 10.1007/s12185-025-04040-x

Mayumi Yoshimori, Miwako Nishio, Ayaka Ohashi, Yuri Maekawa, Runa Shimomaki, Morito Kurata, Kotaro Yoshioka, Takanori Yokota, Ryusuke Nabeshima, Ayako Arai

{"title":"Expression profiling of Epstein-Barr virus-derived microRNA in systemic chronic active EBV disease.","authors":"Mayumi Yoshimori, Miwako Nishio, Ayaka Ohashi, Yuri Maekawa, Runa Shimomaki, Morito Kurata, Kotaro Yoshioka, Takanori Yokota, Ryusuke Nabeshima, Ayako Arai","doi":"10.1007/s12185-025-04040-x","DOIUrl":"https://doi.org/10.1007/s12185-025-04040-x","url":null,"abstract":"Systemic chronic active Epstein-Barr virus disease (sCAEBV) is an intractable disorder characterized by clonal proliferation of EBV-infected T- and NK-cells, leading to persistent systemic inflammation and progression to hemophagocytic lymphohistiocytosis (HLH). The EBV genome encodes 40 mature microRNAs known as miR-BARTs. The expression of miR-BARTs has been reported in other EBV-positive diseases and is associated with tumorigenesis. In this study, we investigated the expression of miR-BARTs in sCAEBV. Expression of miR-BARTs was highly abundant in 4 sCAEBV-derived EBV-positive T- or NK-cell lines and in EBV-infected T- or NK-cells from 23 sCAEBV patients. The highest expression levels were observed for miR-BART7-3p. Sequence analysis revealed no deletions in the EBV genome encoding miR-BARTs. Inhibition of miR-BART7-3p altered the expression of immune-related genes in sCAEBV-derived cell lines. Abundant miR-BART expression was also observed in patients' plasma, with miR-BART7-3p showing the highest levels. Notably, miR-BART7-3p expression was detected in macrophages within the spleen of an sCAEBV patient with HLH. These findings suggest that miR-BARTs are highly expressed and secreted by EBV-infected cells in sCAEBV. We hypothesize that secreted miR-BARTs may be taken up by monocytes, potentially regulating their functions and contributing to inflammation in sCAEBV. Further studies are needed to elucidate these mechanisms.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy. 酪氨酸激酶抑制剂对慢性髓系白血病合并严重扩张型心肌病的心血管毒性。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-07-22 DOI: 10.1007/s12185-025-04041-w

Kenta Hayashino, Naoya Mochizuki, Akihiro Kawatsuki, Yuki Fujiwara, Hiroki Kobayashi, Tomoko Yamasaki, Takeru Asano, Shiro Kubonishi, Yasushi Hiramatsu

{"title":"Cardiovascular toxicity from tyrosine kinase inhibitors in chronic myeloid leukemia with severe dilated cardiomyopathy.","authors":"Kenta Hayashino, Naoya Mochizuki, Akihiro Kawatsuki, Yuki Fujiwara, Hiroki Kobayashi, Tomoko Yamasaki, Takeru Asano, Shiro Kubonishi, Yasushi Hiramatsu","doi":"10.1007/s12185-025-04041-w","DOIUrl":"https://doi.org/10.1007/s12185-025-04041-w","url":null,"abstract":"Tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of patients with chronic myeloid leukemia (CML). However, few patients maintain remission after discontinuing TKIs, and most require long-term treatment. Prolonged use of TKIs is associated with an increased risk of cardiovascular events (CVEs), particularly in patients with pre-existing cardiovascular comorbidities. We present the case of a 37-year-old man with a decade-long history of severe dilated cardiomyopathy that responded inadequately to standard pharmacologic management, who was under consideration for heart transplantation. Following a diagnosis of CML, the patient experienced various CVEs with TKIs, including dasatinib, bosutinib, imatinib, and nilotinib. These agents were discontinued, and treatment was switched to asciminib, a novel agent that targets the myristoyl pocket of the BCR::ABL1 protein distinct from the ATP-binding site targeted by conventional TKIs. This treatment was well tolerated without any CVEs. Given its minimal off-target activity and lower reported incidence of CVEs, asciminib may offer a viable and safer therapeutic option for CML patients with advanced cardiovascular comorbidities, including those awaiting heart transplantation.","PeriodicalId":13992,"journal":{"name":"International Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144690134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

High-dose thiotepa may induce inappropriate secretion of antidiuretic hormone syndrome (SIADH) during conditioning treatment for allogeneic stem cell transplantation. 大剂量硫替帕可能诱导异基因干细胞移植调理治疗过程中抗利尿激素综合征（SIADH）的不适当分泌。

IF 1.7 4区医学

International Journal of Hematology Pub Date : 2025-07-14 DOI: 10.1007/s12185-025-04032-x

Maria Assunta Limongiello, Elisabetta Metafuni, Sabrina Giammarco, Eugenio Galli, Federica Sorà, Francesco Autore, Silvia Baroni, Patrizia Chiusolo, Simona Sica

引用次数: 0